Who
Ebun Garner
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Erasca; General Counsel and SVP, Alphatec Holdings.
In numbers
- Trades disclosed
- 81
- Buys
- 10
- Sells
- 2
- Bought
- $66K
- Sold
- $4.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 7 Jun 2006
- Last trade
- 1 Apr 2026
- Last filed
- 3 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 3 Apr 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Code M | $136K80,000 at $1.70 | filing |
| 1 Apr 2026filed 3 Apr 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Sold | $1.3M80,000 at $16.40 | filing |
| 1 Apr 2026filed 3 Apr 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code M | —80,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code M | —80,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Code M | $136K80,000 at $1.70 | filing |
| 1 Apr 2026filed 3 Apr 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Sold | $1.3M80,000 at $16.40 | filing |
| 29 Jan 2026filed 30 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —560,000 at $0.00 | filing |
| 29 Jan 2026filed 30 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —560,000 at $0.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Code M | $204K120,000 at $1.70 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Sold | $671K120,000 at $5.59 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Code M | $204K120,000 at $1.70 | filing |
| 7 Jan 2026filed 8 Jan 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Sold | $671K120,000 at $5.59 | filing |
| 15 Dec 2025filed 8 Jan 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Code A | $4,6603,902 at $1.19 | filing |
| 15 Dec 2025filed 8 Jan 2026 | ERAS ErascaBiotechnology | SEC FORM 4 Code A | $4,6433,902 at $1.19 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 7 Jan 2025filed 8 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code M | —120,000 at $0.00 | filing |
| 7 Jan 2025filed 8 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code M | —120,000 at $0.00 | filing |
| 13 Dec 2024filed 5 Feb 2025 | ERAS ErascaBiotechnology | SEC FORM 4 Code J | $8,9405,731 at $1.56 | filing |
| 20 Jun 2024filed 21 Jun 2024 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,082 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.